Overview

Ivermectin Solution Bioequivalence Study - Fasted

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of ivermectin solution 1 mg/ml with a marketed reference formulation of ivermectin 3 mg tablets when taken after an overnight fast .The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Consumer and Personal Products Worldwide
Treatments:
Ivermectin